Our Take
A failed trial endpoint is a material fact, not speculation; expect regulators to demand clarity on what went wrong before deciding whether to proceed.
Why it matters
Rare disease approvals hinge on meeting predefined trial endpoints with regulators. A miss here signals either the drug doesn't work as expected or the trial design was misaligned with clinical benefit, both problems that block market access.
Do this week
Biotech investors and M&A teams: pull the full trial protocol and regulatory correspondence before the next investor call so you can quantify whether this is a design failure or a compound failure.
BioMarin's ENPP1 trial failed its primary endpoint
BioMarin acquired a treatment for ENPP1 deficiency, a rare genetic disorder affecting bone mineralization and soft-tissue calcification. The drug was tested in a clinical trial where it failed to meet a goal that regulators consider material to approval decisions. No revised efficacy data, alternative endpoints, or post-hoc analyses have been disclosed that might salvage the application path.
ENPP1 deficiency is a narrow indication. Rare disease trials are typically smaller and rely on well-defined endpoints agreed with the FDA or EMA before enrollment begins. A miss on such an endpoint is not noise; it is a binary outcome.
Regulatory approval now depends on how BioMarin responds
Regulators do not grant approvals on intent or partial data. They require that a pre-specified primary endpoint be met with statistical significance. A failed endpoint does not automatically kill the program, but it does trigger a choice: rerun the trial with a revised design, propose an alternative endpoint backed by new data, or withdraw.
For rare disease programs, the cost of a second trial is often prohibitive. BioMarin will need to demonstrate either that the original endpoint was misdefined (a regulatory conversation, not a science win) or that a secondary measure or subset of patients shows compelling benefit. Without one of those paths, the acquisition's value deflates significantly.
Follow the regulatory filing next
Watch for BioMarin's response to the FDA or EMA in the coming weeks. The company will either request a meeting to discuss a revised path, ask for a Breakthrough Therapy designation to accelerate a redesigned trial, or announce a strategic pause. The filing will show whether management believes the drug works but the trial was wrong, or whether the trial result reflects a real compound problem. That distinction determines whether shareholders and rare disease patients should expect a recovery or a write-down.